Total Raised

$127M

Investors Count

19

Deal Terms

2

Funding, Valuation & Revenue

11 Fundings

EarlySense has raised $127M over 11 rounds.

EarlySense's latest funding round was a Acquired for on February 1, 2021.

EarlySense's latest post-money valuation is from February 2021.

Sign up for a free demo to see EarlySense's valuations in February 2021 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

2/1/2021

Acquired

$XXM

0

FY undefined

1

1/7/2019

Series H

$39M

$XXM

0

FY undefined

2

6/1/2016

Series G

$25M

$XXM

0

FY undefined

18

4/14/2015

Series F - II

$XXM

$XXM

0

FY undefined

10

1/20/2015

Series F

$XXM

$XXM

0

FY undefined

10

Date

2/1/2021

1/7/2019

6/1/2016

4/14/2015

1/20/2015

Round

Acquired

Series H

Series G

Series F - II

Series F

Amount

$39M

$25M

$XXM

$XXM

Investors

Valuation

$XXM

$XXM

$XXM

$XXM

$XXM

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

2

18

10

10

Start free trial
New call-to-action

EarlySense Deal Terms

2 Deal Terms

EarlySense's deal structure is available for 2 funding rounds, including their Acquired from February 01, 2021.

Round

Acquired

Series A

Funding Date

$XXM

$XXM

Pre-Money Valuation

Post-Money Valuation

$XXM

Amount Raised

$XXM

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$XXM

$XXM

Board Voting

$XXM

$XXM

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acquired

$XXM

$XXM

$XXM

$XXM

Series A

$XXM

$XXM

$XXM

$XXM

EarlySense Investors

19 Investors

EarlySense has 19 investors. Hillrom invested in EarlySense's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

1/7/2019

2/1/2021

2
Series H, Acquired (2021)

Corporation

Illinois

6/10/2010

1/7/2019

6
Series C, Series D (2010), Series E (2012), Series F (2015), Series G (2016), Series H (2019)

Venture Capital

Israel

11/12/2012

1/7/2019

4
Series E, Series F (2015), Series G (2016), Series H (2019)

Venture Capital

Illinois

00/00/0000

00/00/0000

BlueRed Partners

Subscribe to see more

Venture Capital

Singapore

00/00/0000

00/00/0000

Wells Fargo Strategic Capital

Subscribe to see more

Corporate Venture

California

First funding

1/7/2019

6/10/2010

11/12/2012

00/00/0000

00/00/0000

Last Funding

2/1/2021

1/7/2019

1/7/2019

00/00/0000

00/00/0000

Investor

BlueRed Partners

Wells Fargo Strategic Capital

Rounds

2
Series H, Acquired (2021)
6
Series C, Series D (2010), Series E (2012), Series F (2015), Series G (2016), Series H (2019)
4
Series E, Series F (2015), Series G (2016), Series H (2019)

Subscribe to see more

Subscribe to see more

Board Seats

Type

Corporation

Venture Capital

Venture Capital

Venture Capital

Corporate Venture

Location

Illinois

Israel

Illinois

Singapore

California

New call-to-action

Compare EarlySense to Competitors

binx health Logo
binx health

binx health focuses on point-of-care molecular diagnostics within the healthcare sector. The company offers diagnostic solutions that provide testing solutions for sexually transmitted infections such as chlamydia and gonorrhea. binx health was formerly known as Atlas Genetics. It was founded in 2005 and is based in Cambridge, Massachusetts.

N
NIR Diagnostics

NIR Diagnostics is developing a diagnostic device to quantitatively assess the progress of the wound healing process. Per the company, the device has the potential to be a more accurate, more rapid, and less expensive method of wound assessment compared to those currently on the market.

E
Exotic Technologies

After two years of development, testing and continuous improvement and trials at various hospitals, INFLO Infusion Flow Rate Monitor was introduced. INFLO is a microprocessor-controlled device with high level of accuracy, which can be used to monitor the infusion flow rate. Its low cost and low operating expenses as well as long life cycle aims to make it an alternative to the expensive infusion monitoring devices and aims to give accuracy and safety with inexpensive infusion sets.

S
SonoMedix

SonoMedix is developing a device to monitor blood coagulation and hemostatic status, using NanoAcoustic Blood Analyzer (NABA) technology licensed from Drexel University. SonoMedix is developing a working NABA-based prototype of a device to be used at home to measure the prothombin time, a measure of blood coagulation, in patients taking the anticoagulant drug, warfarin (Coumadin ). The device will allow the patients who need to perform this testing to use a smaller amount of blood than currently marketed devices, which will allow them to obtain blood from sites other than fingers, reducing the pain of obtaining the sample. The small sample size is currently being validated.

F
Findthedot

findtheDOT designs and develops technology to match medications to patients and physician orders. The Company's printed code mark and portable, wireless code reader provide a practical means of validating medications at the patient bedside.

VivoMetrics Logo
VivoMetrics

VivoMetrics provides continuous ambulatory monitoring products and services for the collection, analysis, and reporting of patient specific physiologic data serving pharmaceutical, biotechnology, and device companies.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.